Kymera Therapeutics, Inc. Q3 FY2026 earnings call

• KT621 (STAT6 Degrader) Progress: Completed the 16-week placebo-controlled portion of the Phase 2b Atopic Dermatitis (AD) study (BROADEN II), with data expected by year-end. Enrollment in the open-label extension (OLE) is at 98% among eligible patients. Phase III planning for AD is underway, targeting initiation by mid-2027 pending supportive data and FDA alignment. The Phase 2b Asthma study (BREATH) continues enrollment, with top-line results expected in late 2027.
• KT579 (IRF5 Degrader) Clinical Data: Reported positive Phase 1 Healthy Volunteer results. KT579 demonstrated robust, sustained degradation of IRF5 (>90% median reduction) in blood and skin with once-daily dosing. Functional modulation was observed across three key immune pathways: inflammatory cytokines, interferon response (98% inhibition of IFN-beta), and B-cell biology. The drug showed a favorable safety profile comparable to placebo, with no serious adverse events.
• Strategic Direction: Management emphasized the potential for KT621 to expand the addressable market for moderate-to-severe AD by offering a safe, effective oral alternative to injectable biologics, potentially reaching millions of untreated patients. For KT579, the program will advance into a Phase 1b lupus trial (LUMORA) early next year. The company plans to disclose its next pipeline program and broader development strategy beyond lupus in 2027.
• Pipeline & Partnerships: Partner programs with Sanofi (KT485, IREC4 degrader) and Gilead (KT200, CDK2 molecular glue) are progressing as planned. The internal research pipeline aims to advance one new program toward development candidate status annually.

Chimera Therapeutics operates as a single business segment focused on the discovery and development of oral degrader medicines for inflammatory diseases. As a pre-commercial clinical-stage company, it does not report revenue from product sales or collaboration milestones in the third quarter of 2026, as all deferred revenue from previous partnerships with Sanofi and Gilead was fully recognized in Q2. The company reported Research and Development (R&D) expenses of $128.5 million for the quarter. The firm ended September with approximately $1.6 billion in cash, cash equivalents, and investments, providing an operational runway into 2029.

• Financial Runway: No explicit financial guidance provided; however, management confirmed that current cash reserves ($1.6 billion) provide a runway into 2029, covering KT579 Phase 1b and initial stages of KT621 Phase III studies.
• Clinical Milestones: Expects to report KT621 Phase 2b AD data by year-end 2026. Plans to initiate KT621 Phase III studies in AD by mid-2027, contingent on regulatory alignment. KT579 is scheduled to enter Phase 1b lupus trials early in 2027.
• Operating Expenses: CFO indicated that R&D expenses will see gradual but consistent increases through 2027, accelerating significantly upon the start of the KT621 Phase III program.

• Regulatory and Clinical Uncertainty: Success of KT621 Phase III and KT579 Phase 1b depends on achieving efficacy targets and meeting regulatory requirements. Cross-trial comparisons to existing therapies (e.g., Dupilumab) are inherently flawed and may not predict commercial success.
• Market Adoption Risks: While oral formulations may expand the market, adoption barriers exist if patients and physicians do not perceive the disease severity to warrant advanced therapy, or if efficacy does not meet expectations relative to biologics.
• Safety Concerns: Potential risks include conjunctivitis (mechanistically expected for STAT6 inhibitors) and infections (monitored closely for IRF5 degradation). Long-term safety profiles remain to be established in patient populations.
• Competitive Landscape: The immunology space is highly competitive with numerous biologics and emerging oral therapies. Differentiation requires demonstrating superior tolerability or market expansion capabilities rather than just head-to-head efficacy.

Q: Analyst asked about the success criteria for the KT579 Phase 1b LUMORA lupus trial and dose selection, noting saturation occurred at dose level 3.

A: Management stated the primary goal is to demonstrate IRF5 modulation in active lupus disease without ex vivo stimulation, validating the target's relevance. They plan to evaluate biomarker movement in inflammatory, interferon, and B-cell pathways, alongside clinical outcomes. Regarding dose selection, they retained several options above the 85% degradation threshold needed for biological effect, promising to announce the chosen dose when launching the trial. They also confirmed that steroid tapering is incorporated into the study design.

Q: Analyst inquired about the potential for KT621 to expand the Atopic Dermatitis market and whether similar expansion could occur in asthma or COPD.

A: CEO Nello Mainolfi highlighted that KT621 represents the first safe, effective oral option for Type 2 inflammation, which could transform treatment by attracting patients who avoid injectable biologics due to perceived severity or safety concerns. He noted that even modest efficacy compared to biologics could drive significant market expansion, citing examples like Agio in psoriasis where most prescriptions are new patients. This logic applies to other indications like asthma and EoE, where oral options could capture patients currently underserved by injectables.

Q: Analyst asked if KT579 development should focus on specific indications beyond lupus, such as IBD, Sjogren's, or RA, based on the biomarker data.

A: CMO Terrence Rooney explained that strong genetic links support IRF5's role in these diseases. The observed modulation of pro-inflammatory cytokines, type 1 interferon, and B-cell biology provides a broad waterfront of opportunity. Specifically, he noted relevance to IBD via TNF-alpha/IL-23 pathways, Sjogren's via interferon signatures, and RA via B-cell mechanisms. CEO Mainolfi added that while lupus is the immediate focus, the company expects to share more comprehensive late-development strategies for other indications in early 2027.

Q: Analyst questioned measures taken to mitigate high placebo response rates in the KT621 BROADEN II AD study.

A: CMO Rooney emphasized that the company prioritized quality over speed, resulting in early enrollment. Mitigation strategies included careful site and investigator selection, controlling for concomitant therapies and prior medications, and rigorous patient selection to ensure moderate-to-severe AD diagnosis. Despite tight inclusion criteria, enthusiasm for an oral option drove rapid enrollment, allowing the team to complete the placebo-controlled portion ahead of schedule.

Q: Analyst asked about the expectation for conjunctivitis incidence in KT621 data and identified the biggest catalyst for 2027.

A: CEO Mainolfi reiterated that conjunctivitis is mechanistically coherent with IL-4N13 biology and is expected; if absent, it would require explanation, but the company is waiting for the full data readout to discuss this. Regarding 2027 catalysts, he identified the Phase 2b Asthma data (expected late 2027) as the biggest upcoming event, which will determine the initiation of multiple Phase III programs in asthma and other respiratory indications.